Market
Where will RAPT Therapeutics rank in market cap among biotechnology companies by June 30, 2025?
2
Resolution / Starting Odds
Top 50 • 25%
Top 100 • 25%
Top 200 • 25%
Below Top 200 • 25%
Market cap data from financial news outlets or stock exchange listings
Story
RAPT Therapeutics Announces $150 Million Private Placement at $0.85/Share, 90.4% Pre-Market Surge, and License Agreement with Shanghai Jemincare
Dec 23, 2024, 01:31 PM
RAPT Therapeutics has announced a $150 million private placement, which includes 176.5 million shares and warrants priced at $0.85 per share. The company also entered an exclusive license agreement with Shanghai Jemincare for its novel long-acting anti-IgE antibody, JYB1904 (RPT904). Under this agreement, RAPT will retain worldwide rights to the drug, excluding mainland China, Hong Kong, Macau, and Taiwan. Jemincare will receive a $35 million upfront payment and could earn up to $672.5 million in milestone payments. Following these announcements, RAPT's stock experienced a significant pre-market increase of 90.4% and was up 74% during trading hours.
View original story
Similar markets
Top 10 • 25%
Top 5 • 25%
Top 20 • 25%
Below Top 20 • 25%
Daiichi Sankyo • 25%
Roche • 25%
Pfizer • 25%
AstraZeneca • 25%
Outside Top 10 • 25%
Top 3 • 25%
Top 5 • 25%
Top 10 • 25%
$1 billion to $5 billion • 25%
More than $5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
2nd • 25%
1st • 25%
4th or lower • 25%
3rd • 25%
Performs in line with the biotech index • 25%
Outperforms the biotech index • 25%
Highly volatile with no clear trend • 25%
Underperforms the biotech index • 25%
Gilead Sciences • 25%
Biogen • 25%
Other Biopharma Companies • 25%
Vertex Pharmaceuticals • 25%
Below 20th • 25%
Top 5 • 25%
6th-10th • 25%
11th-20th • 25%
$5B to $10.2B • 25%
$10.2B to $15B • 25%
Above $15B • 25%
Below $5B • 25%
1st • 25%
3rd • 25%
4th or lower • 25%
2nd • 25%
$20 billion • 25%
Other • 25%
$15 billion • 25%
$25 billion • 25%
4th or lower • 25%
2nd • 25%
1st • 25%
3rd • 25%